Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study

被引:64
作者
O'Malley, CD
Cress, RD
Campleman, SL
Leiserowitz, GS
机构
[1] No Calif Canc Ctr, Union City, CA 94587 USA
[2] Inst Publ Hlth, Calif Canc Registry, Sacramento, CA USA
[3] Canc Registry No Calif, Chico, CA USA
[4] Univ Calif Davis, Ctr Med, Sacramento, CA 95817 USA
关键词
ovarian cancer; survival; chemotherapy;
D O I
10.1016/j.ygyno.2003.08.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The objective was to identify demographic, clinical, and provider characteristics that might influence cancer survival in a cohort of Northern California women using a population-based cancer registry. Methods. We used California Cancer Registry data to evaluate survival in 1051 Northern California women who were diagnosed with epithelial ovarian cancer between 1994 and 1996 and underwent a surgical procedure for their cancer. Chemotherapy data from the cancer registry were supplemented with a physician survey and medical record review. Database linkages with census and hospital discharge data provided socioeconomic and comorbidity measures. Kaplan-Meier method was used to generate survival curves and multivariate Cox proportional hazard models were used to evaluate the effect of different factors on survival. Results. Crude 5-year survival was 82, 57, 28, and 10% for women with FIGO stage IC, 11, 111, and IV disease, respectively. Adverse survival was most strongly influenced by advanced stages III and IV with a hazards ratio ranging from 8 to 11.8 compared to stage IC disease. Multivariate analysis also identified other adverse factors including high grade and other adverse histologies, age over 45, and rural location. Chemotherapy decreased the risk of death by 50% if the patient had advanced-stage disease. Medical comorbidity increased the risk of death by 40%. Survival was not influenced by race/ethnicity, socioeconomic status, physician specialty, or hospital characteristics. Conclusion. Advanced age remains an adverse prognostic factor even after adjustment for treatment and comorbidity factors. These results also suggest that there may be important regional differences in ovarian cancer survival. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:608 / 615
页数:8
相关论文
共 44 条
  • [1] AVERETTE HE, 1993, CANCER, V71, P1629
  • [2] Ovarian cancer:: an institutional review of patterns of care, health insurance and prognosis
    Balli, S
    Fey, MF
    Hänggi, W
    Zwahlen, D
    Berclaz, G
    Dreher, E
    Aebi, S
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (16) : 2061 - 2068
  • [3] Ethnic differences in survival among women with ovarian carcinoma
    Barnholtz-Sloan, JS
    Tainsky, MA
    Abrams, J
    Severson, RK
    Qureshi, F
    Jacques, SM
    Levin, N
    Schwartz, AG
    [J]. CANCER, 2002, 94 (06) : 1886 - 1893
  • [4] Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital
    Bjorge, T
    Engeland, A
    Sundfor, K
    Trope, CG
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (07) : 777 - 781
  • [5] Natural history of stage IV epithelial ovarian cancer
    Bonnefoi, H
    A'Hern, RP
    Fisher, C
    Macfarlane, V
    Barton, D
    Blake, P
    Shepherd, JH
    Gore, ME
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 767 - 775
  • [6] Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995
    Brenner, H
    Stegmaier, C
    Ziegler, H
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (02) : 109 - 113
  • [7] Colombo N, 2003, J NATL CANCER I, V95, P125
  • [8] Patterns of chemotherapy use for women with ovarian cancer: A population-based study
    Cress, RD
    O'Malley, CD
    Leiserowitz, GS
    Campleman, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1530 - 1535
  • [9] DESOUZA PL, 1992, HEMATOL ONCOL CLIN N, V6, P761
  • [10] Survival of European women with gynaecological tumours, during the period 1978-1989
    Gatta, G
    Lasota, MB
    Verdecchia, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) : 2218 - 2225